{"id":2544,"date":"2019-11-04T08:54:48","date_gmt":"2019-11-04T07:54:48","guid":{"rendered":"https:\/\/ibb.uab.cat\/?p=2544"},"modified":"2019-11-04T08:59:02","modified_gmt":"2019-11-04T07:59:02","slug":"la-marato","status":"publish","type":"post","link":"https:\/\/ibb.uab.cat\/index.php\/2019\/11\/04\/la-marato\/","title":{"rendered":"La Marat\u00f3 de TV3 : Dr. Antonio Villaverde Corrales “Nanomedicines humanitzades selectivament dirigides a matar les c\u00e8l\u00b7lules tumorals CXCR4+ per al tractament de la leuc\u00e8mia mieloide aguda”"},"content":{"rendered":"

\"\"<\/strong>A l’edici\u00f3 2018, dedicada al c\u00e0ncer, s’hi van presentar 192 projectes, que van ser avaluats per 149 cient\u00edfics d’\u00e0mbit internacional especialistes en aquesta mat\u00e8ria en funci\u00f3 de la seva qualitat, metodologia i rellev\u00e0ncia. La gesti\u00f3 de l’avaluaci\u00f3 la va dur a terme l’Ag\u00e8ncia de Qualitat i Avaluaci\u00f3 Sanit\u00e0ries de Catalunya, del Departament de Salut.<\/span>
\nD’acord amb la proposta de la Comissi\u00f3 Assessora Cient\u00edfica de la Fundaci\u00f3 La Marat\u00f3 de TV3, el Patronat va acordar distribuir 13.149.870,76 \u20ac entre els 43 projectes de recerca cient\u00edfica d’excel\u00b7l\u00e8ncia seg\u00fcents:<\/span><\/h2>\n

\u00a0<\/h2>\n

Nanomedicines hum\"\"anitzades selectivament dirigides a matar les c\u00e8l\u00b7lules tumorals CXCR4+ per al tractament de la leuc\u00e8mia mieloide aguda.<\/span><\/h2>\n

Dr. Antonio Villaverde Corrales<\/p>\n

\u201cSelectively humanized nanomedicines aimed at killing CXCR4 + tumor cells for the treatment of acute myeloid leukemia<\/em>\u201d \u00a0is one of the Project awarded by La Marat\u00f3 TV3 Foundation and is participated by\u00a0Dr. Antonio Villaverde, Estrategic of NANBIOSIS U1 Protein Production Platform<\/a>\u00a0(PPP)<\/a><\/p>\n

The main objective of the project is the design and validation of humanized protein nanoparticles for the targeted delivery of antitumoral drugs for the treatment of acute myeloid leukemia. This will be done by the generation of protein-based nanoconjugates that will be targeted to the cytokine receptor CXCR4, overexpressed in this human neoplasia. The drugs will consist in a protein part, that will ofer nanoscale size, stability and CXCR4-targeting, and a small molecular weight chemical that will perform the cytotoxic effect over tumoral cells.\u00a0The Protein Production Platform (U1 of NANBIOSIS)<\/strong><\/a>, will have a critical role in the design and production of the protein amounts required for the\u00a0in vivo<\/em>\u00a0experiments, that will be performed at the Institut de Recerca of Sant Pau Hospital.<\/strong><\/p>\n

In the 2018 La Marat\u00f3 TV3 edition, dedicated to cancer, 192 projects were presented, which were evaluated by 149 international scientists specialized in this field based on their quality, methodology and relevance. The management of the evaluation was carried out by the Health and Quality Assessment Agency of Catalonia, from the Department of Health. In accordance with the proposal of the Scientific Advisory Commission of the La Marat\u00f3 de TV3 Foundation, the Board agreed to distribute 13,149,870.76\u20ac among the 43 scientific research projects.<\/p>\n

The Project \u201cSelectively humanized nanomedicines aimed at killing CXCR4 + tumor cells for the treatment of acute myeloid leukemia<\/em>\u201c. Will be developed by the research groups led by:<\/p>\n